

Effects of U-50 488H, a κ -agonist, on action potentials of isolated ventricular papillary muscle of guinea pigs¹

SHENG Jian-Zhong², DONG Hui³, WONG Tak-Ming

(Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong)

ABSTRACT Trans-(+)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzeneacetamide-methanesulfonate-hydrate (U-50 488H), a specific κ -agonist, at 1–10 $\mu\text{mol}\cdot\text{L}^{-1}$ caused concentration-dependent reductions in the action potential duration at 50% and 90% of repolarization (APD₅₀ and APD₉₀) without modifying the resting potential (RP), the action potential amplitude (APA) and the maximal upstroke velocity (V_{max}). The effects were attenuated by (–)-(1R,5R,9R)-5,9-diethyl-2-(3-furylmethyl)-2L-hydroxy-6,7-benzomorphan (Mr 2266 BS, 1 $\mu\text{mol}\cdot\text{L}^{-1}$), a specific κ -antagonist which itself had no effect on the action potentials of the ventricular papillary muscle of guinea pigs, indicating that U-50 488H at 1–10 $\mu\text{mol}\cdot\text{L}^{-1}$ acts via specific cardiac κ -receptors. At 100 $\mu\text{mol}\cdot\text{L}^{-1}$, U-50 488H not only shortened APD₅₀ and APD₉₀, but also reduced RP, APA, and V_{max} , which were not attenuated by Mr 2266 BS (1 $\mu\text{mol}\cdot\text{L}^{-1}$) suggesting that the effects of U-50 488H at 100 $\mu\text{mol}\cdot\text{L}^{-1}$ were probably non-specific.

KEY WORDS U-50 488H; Mr 2266 BS; endorphin receptors; action potentials; papillary muscles; guinea pigs

Trans-(+)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzeneacetamide-methanesulfonate-hydrate (U-50 488H), a specific κ -agonist, induces arrhythmias in the isolated perfused rat hearts and the arrhythmogenic effect is attenuated by (–)-(1R,5R,9R)-5,9-diethyl-2-(3-furylmethyl)-2L-hydroxy-6,7-benzomorphan (Mr 2266

BS), a specific κ -antagonist⁽¹⁻³⁾. However, it is not clear whether the effects are opioid receptor-mediated although it was found that U-50 488H at 10 $\mu\text{mol}\cdot\text{L}^{-1}$ affects action potentials, twitch contraction, and calcium influx in guinea pig ventricular myocytes⁽⁴⁾. In the present study, we investigated the effects of U-50 488H on action potentials of ventricular papillary muscle of guinea pigs and more importantly studied whether the effects were attenuated by a specific κ -antagonist, Mr 2266 BS in order to determine if the effect of U-50 488H is opioid receptor-mediated.

MATERIALS AND METHODS

Twelve guinea pigs (285 \pm s 25 g) of both sexes were stunned. The hearts were quickly placed in 4°C Tyrode's solution. The right papillary muscle was superfused with Tyrode's solution bubbled with 95% O₂ + 5% CO₂ at a rate of 8–10 ml·min⁻¹ (34.5 \pm 0.5 °C). Tyrode's solution was made of: NaCl 137, NaHCO₃ 11.9, NaH₂PO₄ 0.44, MgCl₂ 0.5, CaCl₂ 1.0, KCl 4, and glucose 5 mol·L⁻¹, pH 7.4.

The muscle was electrically stimulated at 1 Hz with rectangular pulses (0.1 ms in duration, 1.5 times threshold) delivered through a bipolar silver electrode. Transmembrane action potentials were recorded using conventional microelectrode techniques. The action potential was displayed on a storage oscilloscope (COS5020-ST). The variables measured were RP, APA, APD₅₀, APD₉₀, and V_{max} which was determined by an electronic differentiating circuit. The muscles were allowed to equilibrate in Tyrode's solution for 1–2 h before exposure to drugs.

In one protocol, action potentials were recorded before or 20 min after cumulative addition of U-50 488H 1, 10, 100 $\mu\text{mol}\cdot\text{L}^{-1}$. In another protocol, action potentials were recorded when muscle

Received 1993-04-05

Accepted 1993-09-10

¹ Supported by a CRCG grant of HKU to TM Wong.

² Recipient of a fellowship from Sun Yat Sen Foundation, now in Department of Physiology, Zhejiang Medical University, Hangzhou 310006, China.

³ Department of Biophysics, School of Basic Medical Sciences, Shanghai Medical University, Shanghai 200032, China.

were perfused with Tyrode's solution containing Mr 2266 BS ($1 \mu\text{mol} \cdot \text{L}^{-1}$) at 5 min before and after addition of U-50 488H.

U-50 488H and Mr 2266 BS were kindly supplied by Upjohn Co and Boehringer Ingelheim Co, respectively. All chemicals used were AR.

Data were obtained only from preparations in which continuous microelectrode impalements were maintained throughout the experiment. The data were analysed with paired Student's *t* test.

RESULTS

U-50 488H at $1-100 \mu\text{mol} \cdot \text{L}^{-1}$ shortened both APD_{50} and APD_{90} in a dose dependent manner. At $100 \mu\text{mol} \cdot \text{L}^{-1}$, it also reduced RP, APD, and V_{max} (Tab 1 and Fig 1a). The effects of U-50 488H at $1-10 \mu\text{mol} \cdot \text{L}^{-1}$ on APD were attenuated by Mr 2266 BS at $1 \mu\text{mol} \cdot \text{L}^{-1}$ (Tab 1 and Fig 1b), which alone produced no significant change on the action potentials when superfused for up to 2 h (Data not shown). The effects of U-50 488H at $100 \mu\text{mol} \cdot \text{L}^{-1}$ were not affected by Mr 2266 BS significantly (Tab 1 and Fig 1b).

DISCUSSION

The present study showed that U-50 488H led to a Mr 2266 BS-reversible shortening of APD of the ventricular papillary muscle of guinea pigs at $1-10 \mu\text{mol} \cdot \text{L}^{-1}$, which is in agreement with our previous findings that U-50 488H induces arrhythmias in the isolated perfused rat heart and that the arrhythmogenic effect is attenuated by Mr 2266 BS⁽³⁾. The results indicate that the effects of the drug at this dose range are via specific κ -opioid receptors. Although the shortening of APD does not always result in arrhythmia, our findings suggest that the arrhythmogenic effect of U-50 488H may be related to the shortening of APD^(3,7). However, the mechanism of action of U-50 488H on shortening of APD and its contribution to arrhythmia is not




Fig 1. Effects of U-50 488H on action potentials of ventricular papillary muscle of guinea pigs in the absence (a) and the presence (b) of Mr 2266 BS at $1 \mu\text{mol} \cdot \text{L}^{-1}$. Concentration of U-50 488H ($\mu\text{mol} \cdot \text{L}^{-1}$): A: 0; B: 1; C: 10; D: 100. The action potential profile in the presence of Mr 2266 BS at $1 \mu\text{mol} \cdot \text{L}^{-1}$ was the same as that in the absence of the antagonist (not shown). Driving rate: 1 Hz.

very clear.

At the concentration of $100 \mu\text{mol} \cdot \text{L}^{-1}$, U-50 488H not only shortened APD, but also RP, APA, and V_{max} and the effects were not antagonized by Mr 2266 BS. The result is in agreement with the observations by duBell and Lakatta⁽⁴⁾ although they did not determine if the effects of U-50 488H were antagonized by

Tab 1. Effects of U-50 488H ($\mu\text{mol}\cdot\text{L}^{-1}$) on action potentials of ventricular papillary muscle of guinea pigs in the absence ($n = 8$) and the presence ($n = 4$) of Mr 2266 BS at $1 \mu\text{mol}\cdot\text{L}^{-1}$ $\bar{x} \pm s$. ^a $P > 0.05$, ^b $P < 0.05$, ^c $P < 0.01$ vs 0.

U-50 488H	In the absence of Mr 2266 BS				In the presence of Mr 2266 BS			
	0	1	10	100	0	1	10	100
RP/mV	-91±2	-91±2 ^a	-91±3 ^a	-88±3 ^b	-90±2	-90±3 ^a	-90±1 ^a	-87±1 ^b
APA/mV	134±4	134±8 ^a	133±8 ^a	123±8 ^c	130±3	130±1 ^a	128±5 ^a	117±2 ^c
$V_{\text{max}}/V \cdot s^{-1}$	200±10	200±1 ^a	199±11 ^a	178±14 ^c	200±3	200±3 ^a	199±3 ^a	159±11 ^c
APD ₅₀ /ms	196±12	181±16 ^c	174±17 ^c	152±20 ^c	186±15	188±19 ^a	184±17 ^a	156±6 ^c
APD ₉₀ /ms	240±17	226±20 ^b	221±20 ^c	207±23 ^c	232±14	236±16 ^a	234±15 ^a	210±3 ^b

opioid antagonists. In our previous^{15,63} and present studies, higher concentrations of U-50488H produce effects not antagonized by Mr 2266 BS, suggesting that the effects of the κ -agonist may be most likely non-specific. In conclusion the present study showed the κ -receptor-mediated and non-specific effects of U-50 488H, a specific κ -agonist, on action potential of the guinea pig papillary muscles. Further and more thorough studies are needed to unveil the ionic basis of the effects resulted from activation of cardiac κ -opioid receptors although it has been shown that U-50488H decreases intracellular free calcium transient in myocytes stimulated electrically¹⁸.

REFERENCES

- 1 Lee AYS, Wong TM. Effects of dynorphin₁₋₁₃ on cardiac rhythm and cyclic adenosine monophosphate (cAMP) levels in the isolated perfused rat heart. *Neurosci Lett* 1987; **80**: 289-92.
- 2 Wong TM, Lee AYS. Chronic morphine treatment reduces the incidence of ventricular arrhythmias in the iso-

- lated rat heart induced by dynorphin₁₋₁₃ or myocardial ischemia and reperfusion. *Neurosci Lett* 1987; **77**: 61-5.
- 3 Wong TM, Lee AYS, Tai KK. Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart — an attempt to identify cardiac opioid receptor subtype(s) involved in arrhythmogenesis. *J Mol Cell Cardiol* 1990; **22**: 1167-75.
- 4 duBell WH, Lakatta EG. The effects of the κ -opioid agonist U-50 488H on guinea pig ventricular myocytes. *Biophys J* 1991; **59** (2pt 2): 465a.
- 5 Pugsley MK, Penz WP, Walker MJA, Wong TM. Cardiovascular actions of the κ -agonist, U-50 488H, in the absence and presence of opioid receptor blockade. *Br J Pharmacol* 1992; **105**: 521-6.
- 6 Pugsley MK, Penz WP, Walker MJA, Wong TM. Antiarrhythmic effects of U-50 488H in rats subject to coronary artery occlusion. *Eur J Pharmacol* 1992; **212**: 15-9.
- 7 Peng WJ, Sheridan DJ. Arrhythmias and cellular electrophysiological changes during myocardial "ischemia" and reperfusion. *Cardiovasc Res* 1983; **17**: 363-72.
- 8 Ventura C, Spurgeon H, Lakatta EG, Guarnieri C, Cologrossi MC. κ and δ Opioid receptor stimulation affect cardiac myocyte function and Ca^{2+} release from an intracellular pool in myocytes and neurons. *Circ Res* 1992; **70**: 66-81.